{"id":"1", "jsonData": "{'title':'Metformin Does Not Suppress Serum Thyrotropin by Increasing Levothyroxine Absorption', 'download':'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4589100/pdf/thy.2015.0211.pdf', 'ncbi_ref':'http://www.ncbi.nlm.nih.gov/pubmed/26191653'}", "content": {"mimeType": "application/pdf", "uri": "gs://vijay-enterprise-search-staging/jk-original-10/thy.2015.0211.pdf"}}
{"id":"2", "jsonData": "{'title':'Orteronel for the treatment of prostate cancer', 'download':'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4148348/pdf/nihms612517.pdf', 'ncbi_ref':'https://pubmed.ncbi.nlm.nih.gov/24799061/'}", "content": {"mimeType": "application/pdf", "uri": "gs://vijay-enterprise-search-staging/jk-original-10/nihms612517.pdf"}}
{"id":"3", "jsonData": "{'title':'A phase 1 multiple-dose study of orteronel in Japanese patients with castration-resistant prostate cancer', 'download':'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4305367/pdf/280_2014_Article_2654.pdf', 'ncbi_ref':'https://pubmed.ncbi.nlm.nih.gov/25537627/'}", "content": {"mimeType": "application/pdf", "uri": "gs://vijay-enterprise-search-staging/jk-original-10/280_2014_Article_2654.pdf"}}
{"id":"4", "jsonData": "{'title':'Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5', 'download':'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4879718/pdf/zlj723.pdf', 'ncbi_ref':'https://pubmed.ncbi.nlm.nih.gov/25624429/'}", "content": {"mimeType": "application/pdf", "uri": "gs://vijay-enterprise-search-staging/jk-original-10/zlj723.pdf"}}
{"id":"5", "jsonData": "{'title':'Beyond abiraterone: new hormonal therapies for metastatic castration-resistant prostate cancer', 'download':'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3928129/pdf/cbt-15-149.pdf', 'ncbi_ref':'https://pubmed.ncbi.nlm.nih.gov/24100689/'}", "content": {"mimeType": "application/pdf", "uri": "gs://vijay-enterprise-search-staging/jk-original-10/cbt-15-149.pdf"}}
{"id":"6", "jsonData": "{'title':'Optimal bone health management strategies in patients with prostate cancer', 'download':'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3737681/pdf/IJU-29-89.pdf', 'ncbi_ref':'http://www.ncbi.nlm.nih.gov/pubmed/23956508'}", "content": {"mimeType": "application/pdf", "uri": "gs://vijay-enterprise-search-staging/jk-original-10/IJU-29-89.pdf"}}
{"id":"7", "jsonData": "{'title':'A changing landscape in castration-resistant prostate cancer treatment', 'download':'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3399094/pdf/fendo-03-00085.pdf', 'ncbi_ref':'http://www.ncbi.nlm.nih.gov/pubmed/22826702'}", "content": {"mimeType": "application/pdf", "uri": "gs://vijay-enterprise-search-staging/jk-original-10/fendo-03-00085.pdf"}}
{"id":"8", "jsonData": "{'title':'Therapeutic Fc-fusion proteins and peptides as successful alternatives to antibodies', 'download':'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3225844/pdf/mabs0305_0415.pdf', 'ncbi_ref':'https://pubmed.ncbi.nlm.nih.gov/21785279/'}", "content": {"mimeType": "application/pdf", "uri": "gs://vijay-enterprise-search-staging/jk-original-10/mabs0305_0415.pdf"}}
{"id":"9", "jsonData": "{'title':'Emerging novel therapies in the treatment of castrate-resistant prostate cancer', 'download':'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3104424/pdf/cuaj-2-120.pdf', 'ncbi_ref':'https://pubmed.ncbi.nlm.nih.gov/21470540/'}", "content": {"mimeType": "application/pdf", "uri": "gs://vijay-enterprise-search-staging/jk-original-10/cuaj-2-120.pdf"}}
{"id":"10", "jsonData": "{'title':'Therapeutic drug monitoring: antiarrhythmic drugs', 'download':'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1874159/pdf/bcp0046-0307.pdf', 'ncbi_ref':'https://pubmed.ncbi.nlm.nih.gov/9803978/'}", "content": {"mimeType": "application/pdf", "uri": "gs://vijay-enterprise-search-staging/jk-original-10/bcp0046-0307.pdf"}}